Last updated on
Approach to the Patient with Cancer and Thrombosis
NATF is proud to present this collection of review articles on cancer-associated thrombosis (CAT), published online in The Oncologist. These reviews address several distinct aspects of CAT management, including risk prediction, strategies for CAT prophylaxis and treatment, and approaches to patients with unique clinical challenges. The series concludes with a comprehensive review of cancer-specific guidelines and outlines areas where additional guidance is warranted.
NATF Cancer-Associated Thrombosis Project: Introduction
Jean M. Connors
An outstanding group of medical oncologists, hematologists, cardiologists, and epidemiologists developed a series of manuscripts on management approaches for the prevention and treatment of cancer‐associated venous thromboembolism. This article introduces this multidisciplinary collaborative effort.
Prediction and Prevention of Cancer-Associated Thromboembolism
Alok A. Khorana, Maria T. DeSancho, Howard Liebman, Rachel Rosovsky, Jean M. Connors, Jeffrey Zwicker
The ability to predict risk of cancer‐associated venous thromboembolism (VTE) is critical to determining an optimal thromboprophylaxis treatment strategy. This review describes optimal approaches to risk prediction and patient selection for primary pharmacologic thromboprophylaxis of cancer‐associated VTE, addresses barriers to implementing these practices, and highlights strategies to overcome these barriers.
Treatment of Cancer-Associated Venous Thromboembolism with Low-Molecular-Weight Heparin or Direct Oral Anticoagulants: Patient Selection, Controversies, and Caveats
Casey O’Connell, Carmen P. Escalante, Samuel Z. Goldhaber, Robert McBane, Jean M. Connors, Gary E. Raskob
The management of venous thromboembolism (VTE) in patients with cancer poses challenges for the treating clinician beyond the elevated risks of recurrence and major bleeding. This article summarizes the evidence from clinical trials of low‐molecular‐weight heparin and direct oral anticoagulants that underpins NCCN guidelines, addresses controversies regarding anticoagulant treatment, and offers suggestions for patient selection for treatment.
Approach to Cancer-Associated Thrombosis: Challenging Situations and Knowledge Gaps
Tzu-Fei Wang, Henny H. Billett, Jean M. Connors, Gerald A. Soff
Cancer patients have unique challenges and comorbidities that can lead to increased risks and concerns with anticoagulation. This article reports commonly encountered challenges in patients with cancer‐associated thrombosis, reviews the available literature, and provides practice suggestions.
Update on Guidelines for the Management of Cancer-Associated Thrombosis
Michael B. Streiff, Syed Ali Abutalib, Dominique Farge, Martina Murphy, Jean M. Connors, Gregory Piazza
Numerous guidelines for cancer‐associated thromboembolism have been published. This review compares recommendations from the most recent cancer‐specific guidelines, identifying areas in which guidance is lacking.
NATF thanks Dr. Jean Connors and Aviva Schwartz for leading this effort and Kathryn Mikkelsen and Courtney Anderson for their ongoing support.
This work was funded through an educational grant from:
